Vall d'Hebron Institute of Research, Galatea Clinic Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Barcelona Spain (1994)

Organization Overview

First Clinical Trial
2007
NCT00504491
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

David Garcia-Dorado | Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron | Department of Oncology, Hospital Universitario Vall d´Hebron | Francesc Bosch, MD | Hospital Universitario Vall d´Hebron | HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA | HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA | Hospital Universitari Vall d'Hebron, Barcelona | IOB Institute of Oncology, Vall d´Hebron Institute of Oncology (VHIO) | Liver Unit, Department of Internal Medicine, Hospital Universitario Vall d´Hebron | Medical Oncology Department, Vall d'Hebron Institute of Oncology, CIBERONC | Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital Campus | University Hospital of Vall d'Hebron | Vall de Hebron, Barcelona, Spain | Vall d'Hebron Institut de Recerca (VHIR) | Vall d'Hebron institute of oncology (VHIO), Catalan institute of oncology (Hospitalet) (ICO) | Vall d'Hebron Institute of Research, Galatea Clinic | Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain | Vall d'Hebron University Hospital (HUVH) | VHIO (Vall d'Hebron Institute of Oncology)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Adenocarcinoma, Follicular (Phase 2)

Biliary Tract Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Papillary (Phase 2)

Cholangiocarcinoma (Phase 4)

Communicable Diseases (Phase 2)

Endocrine Gland Neoplasms (Phase 2)

Infarction (Phase 3)

Infections (Phase 2)

Klatskin Tumor (Phase 4)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Mental Disorders (Phase 4)

Myocardial Infarction (Phase 3)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 2)

Pancreatic Neoplasms (Phase 2)

Paraganglioma (Phase 2)

Pheochromocytoma (Phase 2)

Pneumonia (Phase 2)

Pneumonia, Viral (Phase 2)

Problem Behavior (Phase 4)

Thyroid Cancer, Papillary (Phase 2)

Thyroid Carcinoma, Anaplastic (Phase 2)

Thyroid Diseases (Phase 2)

Thyroid Neoplasms (Phase 2)

Viremia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 33